Their study showed that CLL patients with poor prognostic factors, such as ZAP-70 and/or CD38 expression as well as 17p and/or 11q deletion, had a lower percentage of TLR2+/CD19+ cells. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.